1438.1: A Phase 1, open label, dose-escalation study of a DLL3/CD3 T-cell engager (BI 764532) in patients with SCLC and other NECs expressing DLL31,2
1. NCT04429087. https://clinicaltrials.gov/ct2/show/NCT04429087. Accessed April 2024; 2. Gambardella V, et al. NANETS 2023. Oral Presentation 23713.